Edwards Lifesciences Corporation
EW
주식 순위
#476
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
주가
$88.23
시가총액
$50.86B
변동 (1일)
1.08%
변동 (1년)
17.19%
국가
US
거래 Edwards Lifesciences Corporation (EW)
카테고리
Healthcare
Edwards Lifesciences Corporation (EW)의 매출
Jun 2026 기준 매출 TTM: $6.51B
Edwards Lifesciences Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $6.51B입니다. 2024년에 회사는 $5.44B의 수익을 올렸으며 이는 2023년의 $5.01B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Edwards Lifesciences Corporation의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $6.51B | 7.33% |
| 2025 | $6.07B | 11.55% |
| 2024 | $5.44B | 8.57% |
| 2023 | $5.01B | -6.92% |
| 2022 | $5.38B | 2.86% |
| 2021 | $5.23B | 19.29% |
| 2020 | $4.39B | 0.88% |
| 2019 | $4.35B | 16.79% |
| 2018 | $3.72B | 8.37% |
| 2017 | $3.44B | 15.91% |
| 2016 | $2.96B | 18.85% |
| 2015 | $2.49B | 7.35% |
| 2014 | $2.32B | 13.56% |
| 2013 | $2.05B | 7.68% |
| 2012 | $1.90B | 13.17% |
| 2011 | $1.68B | 16.01% |
| 2010 | $1.45B | 9.51% |
| 2009 | $1.32B | 6.76% |
| 2008 | $1.24B | 13.44% |
| 2007 | $1.09B | 5.22% |
| 2006 | $1.04B | 3.92% |
| 2005 | $997.90M | 7.13% |
| 2004 | $931.50M | 8.25% |
| 2003 | $860.50M | 22.23% |
| 2002 | $704.00M | 1.73% |
| 2001 | $692.00M | -13.93% |
| 2000 | $804.00M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $46.59B | 615.34% |
US
|
|
| $35.48B | 444.88% |
IE
|
|
| $25.84B | 296.74% |
US
|
|
| $21.00B | 222.41% |
US
|
|
| - | - |
DE
|
